NEW YORK (TheStreet) -- Syneron Medical (ELOS) shares are up 18.97% to $10.78 in early market trading on Thursday after the aesthetic medical treatment product manufacturer issued upside fourth quarter guidance today.

The Israeli company issued fourth quarter revenue guidance between $72 million and $74 million, beating analysts $67.31 million consensus estimates.

The company's strong guidance reflects expected 50% growth in North American product revenue with 15% growth in the European, Middle East and African regions, and 30% growth in the Asian Pacific region.

Exclusive Report: Jim Cramer's Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The company is set to report its fourth quarter financial results on February 18.

TheStreet Ratings team rates SYNERON MEDICAL LTD as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate SYNERON MEDICAL LTD (ELOS) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and unimpressive growth in net income."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

ELOS Chart ELOS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.